Answer
Pegaspargase (Oncaspar) can cause pancreatitis, including haemorrhagic or necrotising pancreatitis with fatal outcomes; treatment should be discontinued if pancreatitis is suspected and must not be restarted if confirmed.
Sources for this answer
- Oncaspar 750 U/ml powder for solution for injection/infusionServier Laboratories Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked